HC Wainwright restated their buy rating on shares of RegeneRx Biopharmaceuticals Inc. (OTC:RGRX) in a research note issued to investors on Tuesday.

Shares of RegeneRx Biopharmaceuticals (RGRX) opened at 0.275 on Tuesday. The firm has a market capitalization of $29.39 million, a price-to-earnings ratio of 25.000 and a beta of -2.60. RegeneRx Biopharmaceuticals has a 12-month low of $0.22 and a 12-month high of $0.40. The firm’s 50-day moving average is $0.27 and its 200-day moving average is $0.29.

TRADEMARK VIOLATION WARNING: “RegeneRx Biopharmaceuticals Inc. (RGRX) Given Buy Rating at HC Wainwright” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.thecerbatgem.com/2017/08/31/regenerx-biopharmaceuticals-inc-rgrx-given-buy-rating-at-hc-wainwright.html.

About RegeneRx Biopharmaceuticals

RegeneRx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of a therapeutic peptide, Thymosin beta 4 (Tb4), for tissue and organ protection, repair and regeneration. The Company’s segment is the development and marketing of product candidates based on Tb4, an amino acid peptide.

Receive News & Stock Ratings for RegeneRx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RegeneRx Biopharmaceuticals Inc. and related stocks with our FREE daily email newsletter.